Bleomycin has antiviral properties against drug-resistant HIV strains and sensitises virus to currently used antiviral agents

In this study we performed phenotypic assays to assess involvement of the cancer chemotherapeutic agent bleomycin (BLM) in replication inhibition of mutant HIV-1 viral strains. Three clinically relevant mutant HIV variants, including one containing the Q151M mutation conferring multinucleoside resis...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of antimicrobial agents Vol. 27; no. 1; pp. 63 - 68
Main Authors:	Georgiou, Niki A., van der Bruggen, Tjomme, Healy, Derek M.C., van Tienen, Carla, de Bie, Prim, Oudshoorn, Maroeska, Marx, Joannes J.M., van Asbeck, B. Sweder
Format:	Journal Article
Language:	English
Published:	London Elsevier B.V 2006 Amsterdam Elsevier New York, NY
Subjects:	Anti-HIV Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Bleomycin Bleomycin - pharmacology Cells, Cultured Drug Resistance, Viral HIV-1 - drug effects HIV-1 - physiology HIV-1 replication inhibition Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Lamivudine - pharmacology Leukocytes, Mononuclear - virology Medical sciences Microbial Sensitivity Tests Mutant strains Mutation Pharmacology. Drug treatments Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Zidovudine - pharmacology Mutant strains Bleomycin HIV-1 replication inhibition Antineoplastic agent Immunopathology Treatment resistance HIV-1 virus Retroviridae AIDS Immune deficiency Lentivirus Strain Infection Virus Antibiotic Glycopeptide Viral disease Antiviral Replication Inhibitor Mutation Human immunodeficiency virus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In this study we performed phenotypic assays to assess involvement of the cancer chemotherapeutic agent bleomycin (BLM) in replication inhibition of mutant HIV-1 viral strains. Three clinically relevant mutant HIV variants, including one containing the Q151M mutation conferring multinucleoside resistance, were equally as sensitive to BLM as the wild-type HXB2 strain. Long-term incubation of BLM with a wild-type HIV Ba-L strain did not alter the sensitivity of the strain to BLM (IC 50 of BLM 0.64 μM at the beginning of incubation to 0.58 μM). At the same point in time, resistance to lamivudine (3TC) and zidovudine (AZT) was noted. Interestingly, the BLM-treated virus showed hypersensitivity to both AZT and 3TC. Our results suggest a contribution of BLM in viral load reduction in patients receiving both anticancer and antiviral agents and harbouring both wild-type and resistant HIV strains.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0924-8579 1872-7913
DOI:	10.1016/j.ijantimicag.2005.09.008